Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Conditions
- Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
Interventions
- DRUG: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.
- DRUG: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.
- DRUG: Amino acid solution
- DRUG: Lanreotide (Autogel formulation) or Octreotide LAR
Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Collaborators